Cell therapy for acute myocardial infarction--where do we go from here?

Jay H. Traverse, Timothy D. Henry

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Multiple clinical trials have been performed to test the hypothesis that administration of bone-marrow-derived progenitor and stem cells (BMCs) may improve left-ventricular (LV) function following acute myocardial infarction (AMI). These studies have generally confirmed that cell therapy administration can be safely administered; however, consensus has not been reached on whether this approach results in an improvement in LV function or clinical outcomes. Although many of the published studies have been randomized, placebo-controlled trials, many important questions regarding patient selection, methodology and trial design still exist. To date, almost no information has been obtained in regard to optimal dosing and cell type, timing of administration and preferred method of delivery. As a result, current cell therapy administration for AMI finds itself at the crossroads. In this review we have highlighted some of the important questions that remain unanswered in the field of cell therapy after AMI. We believe that future cell therapy trials should attempt to incorporate these important issues in designing upcoming clinical trials in order for the field to move forward.

Original languageEnglish (US)
Pages (from-to)64-70
Number of pages7
JournalJournal of cardiovascular translational research
Issue number1
StatePublished - Mar 2008

Bibliographical note

This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine


Dive into the research topics of 'Cell therapy for acute myocardial infarction--where do we go from here?'. Together they form a unique fingerprint.

Cite this